Aaron DavenportManaging Director
Mr. Davenport plays a leading role in all aspects of the firm’s investment strategy and execution focusing on both the healthcare and specialty chemicals industries. He currently serves as Chairman of the Board of Noramco, Tasmanian Alkaloids, Wavelength Pharmaceuticals and Perimeter Solutions. He previously served as Chairman of the Board of AEB Group, Halo Pharmaceutical and TriTex and a member of the Board of Directors of IBA Molecular and Archroma.
Prior to SK Capital, Mr. Davenport was a Principal at Arsenal Capital Partners where he co-led Arsenal’s healthcare investing efforts and served on the firm’s Operating and Investment Committees. Mr. Davenport’s professional career began in a general management role with CB Richard Ellis/Whittier Partners, where his leadership positions included Director of Business Strategy and Development.
Mr. Davenport was previously the Chairman of Charter Brokerage and previously served on the boards of Bend Research, IRIX Pharmaceuticals, Scientific Protein Laboratories, Priority Solutions, and Innovative Medical Device Solutions.
Mr. Davenport graduated magna cum laude with a B.A. in History from Amherst College and has an M.B.A. from the Tuck School of Business at Dartmouth College.